Last Updated:
10 Mar 2026, 03:29:56 PM (IST)
Medicamen Biotech Limited
NSE: MEDICAMEQ BSE: MEDICAMEQ
NSE
290.50
3.90 (1.36%)
Prev Close
286.6
Open Price
292.3
Volume
26,551
Today Low / High
285.1 / 294.5
52 WK Low / High
280.4 / 544
Range
276 - 305
BSE
289.55
4.05 (1.42%)
Prev Close
285.5
Open Price
290.55
Volume
5,002
Today Low / High
286 / 292.7
52 WK Low / High
277.05 / 545.2
Range
275 - 304
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 290.5 (target range: 276 - 305), reflecting a change of 3.9 (1.36078%). On the BSE, it is listed at 289.55 (target range: 275 - 304), showing a change of 4.05 (1.41856%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Medicamen Biotech Limited Graph
Medicamen Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Medicamen Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 290.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 289.55 | 292.45 | 263.20 - 321.69 |
| 295.34 | 236.27 - 354.41 | ||
| 298.24 | 208.77 - 387.71 | ||
| Bearish Scenario | 289.55 | 286.65 | 257.99 - 315.32 |
| 283.76 | 227.01 - 340.51 | ||
| 280.86 | 196.60 - 365.12 |
Overview of Medicamen Biotech Limited
ISIN
INE646B01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
25,952
Market Cap
4,085,119,878
Last Dividend
1
Official Website
IPO Date
2021-10-27
DCF Diff
587.16
DCF
-252
Financial Ratios Every Investor Needs
Stock Dividend of MEDICAMEQ
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-19 | September 19, 25 | 1 | 1 | 2025-09-19 | 2025-10-25 | |
| 2024-09-19 | September 19, 24 | 1 | 1 | 2024-09-19 | 2024-10-26 | |
| 2023-09-20 | September 20, 23 | 1 | 1 | 2023-09-20 | 2023-10-27 | |
| 2022-09-19 | September 19, 22 | 1 | 1 | 2022-09-20 | 2022-10-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 162.55 Cr | 123.56 Cr | 38.99 Cr | 0.2399 | 0.00 Cr | 6.92 Cr | 6.79 Cr | 7.11 Cr | 5.59 | 20.10 Cr | 0.0437 |
| 2024-03-31 | 179.31 Cr | 94.11 Cr | 85.20 Cr | 0.4752 | 0.00 Cr | 6.68 Cr | 51.68 Cr | 10.93 Cr | 8.63 | 24.57 Cr | 0.0610 |
| 2023-03-31 | 140.87 Cr | 72.09 Cr | 68.77 Cr | 0.4882 | 1.41 Cr | 4.38 Cr | 18.25 Cr | 14.84 Cr | 11.73 | 27.71 Cr | 0.1054 |
| 2022-03-31 | 115.45 Cr | 67.46 Cr | 47.99 Cr | 0.4157 | 1.05 Cr | 4.48 Cr | 18.71 Cr | 14.90 Cr | 12.19 | 25.81 Cr | 0.1290 |
| 2021-03-31 | 112.72 Cr | 79.20 Cr | 33.52 Cr | 0.2974 | 0.69 Cr | 3.56 Cr | 17.50 Cr | 12.13 Cr | 9.93 | 20.43 Cr | 0.1076 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.76 Cr | 296.89 Cr | 84.10 Cr | 212.7809 Cr | 33.25 Cr | 29.49 Cr | 62.14 Cr | 86.12 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 78.1654 Cr |
| 2024-03-31 | 14.79 Cr | 294.55 Cr | 87.57 Cr | 206.9843 Cr | 31.11 Cr | 16.33 Cr | 59.38 Cr | 90.95 Cr | 0.00 Cr | 0.00 Cr | 1.22 Cr | 84.5554 Cr |
| 2023-03-31 | 20.78 Cr | 278.52 Cr | 85.10 Cr | 193.4141 Cr | 25.71 Cr | 3.40 Cr | 45.06 Cr | 91.76 Cr | 4.39 Cr | 0.00 Cr | 1.11 Cr | 82.5735 Cr |
| 2022-03-31 | 3.82 Cr | 225.69 Cr | 79.22 Cr | 146.4698 Cr | 25.80 Cr | 21.97 Cr | 27.01 Cr | 92.12 Cr | 6.63 Cr | 0.00 Cr | 0.87 Cr | 72.6908 Cr |
| 2021-03-31 | 3.89 Cr | 194.01 Cr | 61.12 Cr | 132.8895 Cr | 18.82 Cr | 17.16 Cr | 5.20 Cr | 89.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 53.2740 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -9.8586 Cr | -2.3782 Cr | 1.2159 Cr | -11.9319 Cr | 2.8940 Cr | 3.7594 Cr | -2.0733 Cr | 7.1082 Cr | 1.6224 Cr | -1.2715 Cr | -2.7612 Cr |
| 2024-03-31 | -6.7438 Cr | -5.5629 Cr | 6.3135 Cr | -13.0310 Cr | -5.9932 Cr | 14.7856 Cr | -6.2872 Cr | 10.9310 Cr | 6.6345 Cr | -1.2651 Cr | -14.3179 Cr |
| 2023-03-31 | -6.2928 Cr | -5.8804 Cr | 29.1273 Cr | -12.8939 Cr | 16.9540 Cr | 20.7788 Cr | -6.6011 Cr | 14.8441 Cr | -0.1659 Cr | -1.2651 Cr | -18.0476 Cr |
| 2022-03-31 | 4.1091 Cr | -8.4728 Cr | 4.2979 Cr | -4.4991 Cr | -0.0658 Cr | 3.8248 Cr | -8.6082 Cr | 14.8971 Cr | -1.3310 Cr | -1.2217 Cr | -21.8059 Cr |
| 2021-03-31 | 12.7716 Cr | -17.8126 Cr | 5.8389 Cr | -5.1943 Cr | 0.7979 Cr | 3.8906 Cr | -17.9659 Cr | 12.1294 Cr | 4.0461 Cr | -0.6108 Cr | 11.7537 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 46.91 Cr | 33.91 Cr | 13.00 Cr | 0.2771 | 2.55 Cr | 2.19 Cr | 1.61 | 4.38 Cr | 0.0466 |
| 2025-09-30 | 47.17 Cr | 33.84 Cr | 13.33 Cr | 0.2826 | 3.30 Cr | 2.67 Cr | 1.56 | 5.53 Cr | 0.0565 |
| 2025-06-30 | 43.04 Cr | 22.71 Cr | 20.33 Cr | 0.4723 | 2.81 Cr | 2.15 Cr | 1.18 | 5.09 Cr | 0.0500 |
| 2025-03-31 | 29.61 Cr | 22.64 Cr | 6.97 Cr | 0.2354 | -2.09 Cr | 2.42 Cr | 1.90 | 3.62 Cr | 0.0816 |
| 2024-12-31 | 45.14 Cr | 22.32 Cr | 22.82 Cr | 0.5055 | 4.50 Cr | 2.92 Cr | 2.30 | 6.85 Cr | 0.0647 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 43.68 Cr | 0.00 Cr | 43.68 Cr | 77.57 Cr | 68.77 Cr | 223.41 Cr | 84.98 Cr | 367.11 Cr | 91.70 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 3.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -212.78 Cr |
| 2025-03-31 | 3.76 Cr | 0.00 Cr | 3.76 Cr | 68.90 Cr | 62.14 Cr | 164.55 Cr | 86.12 Cr | 296.89 Cr | 84.10 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -215.91 Cr |
| 2024-09-30 | 6.42 Cr | 0.00 Cr | 6.42 Cr | 4.24 Cr | 59.97 Cr | 156.77 Cr | 87.80 Cr | 288.51 Cr | 72.60 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 1.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 3.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Head of Pharmacovigilance & Operations
Aneek Gupta
Gender: Not Specified
Year Born:
Whole-Time Director
Ashwani Kumar Sharma
Gender: male
Year Born: 1959
Chief Financial Officer
Chandan Kumar
Gender: male
Year Born:
Chief Executive Officer
Rajesh Madan Pharma
Gender: male
Year Born:
Compliance Officer & Company Secretary
Parul Choudhary
Gender: female
Year Born:
FAQs about Medicamen Biotech Limited
Who is the CEO of the company?
The CEO is Rajesh Madan Pharma.
What is the current market price of the stock?
The current price is ₹301.20.
What is the 52-week price range?
The range is ₹288.15-544.
What is the market capitalization of the company?
The market capitalization is ₹408.51 crores.
What is the dividend yield?
The dividend yield is 0.33%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 43.35.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Medicamen Biotech Limited (ISIN: INE646B01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹408.51 crores and an average daily volume of 25,952 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.